Steris stock and long-term growth. Investors focus on healthcare technology and sterilization demand
Steris plc is a global provider of infection prevention and procedural solutions, offering investors exposure to the growing demand for sterilization, surgical equipment, and hospital productivity. The company's business model combines manufacturing of specialized equipment with field service and consumable products, generating recurring revenue streams. Steris serves customers worldwide and its offerings are supported by increasing procedure volumes, aging populations, and stricter hygiene standards, making it an attractive option for long-term investors in healthcare infrastructure.
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 13,500 Shares of STERIS plc $STE
Fjarde AP Fonden, the Fourth Swedish National Pension Fund, significantly increased its stake in STERIS plc (NYSE:STE) during the first quarter, purchasing an additional 13,500 shares, bringing its total holding to 27,566 shares valued at approximately $6.1 million. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $278 for STERIS. The company recently reported quarterly EPS of $2.83, slightly below estimates, with revenue of $1.59 billion, and declared a quarterly dividend of $0.63 per share.
AMSCO 400 Surgical Table from Steris plc - US hospitals lean on reliable flexibility
The article highlights the AMSCO 400 Surgical Table from Steris plc, emphasizing its robust features like a 1,000 lb weight capacity, adjustable height, and imaging support, which cater to the demanding workflows and increasingly heavier patient population in US hospitals. It positions the AMSCO 400 as a crucial product that contributes to Steris's recurring revenue through equipment replacement cycles, service agreements, and accessory sales, reinforcing the company's market position beyond just sterilization products. The AMSCO 400 is presented as a practical, durable, and flexible solution for operating rooms and ambulatory surgery centers, designed to optimize efficiency and infection control.
Steris plc shares hold steady. Business context stays in view.
Steris plc's stock remains stable, driven by its core business in healthcare and life sciences equipment, focusing on sterilization and infection prevention. The company's compliance-driven model and recurring demand from hospitals and laboratories are key factors for investors. The article emphasizes the importance of the company's operating base and market setting over short-term price fluctuations.
Strs Ohio Purchases 6,196 Shares of STERIS plc $STE
Strs Ohio increased its stake in STERIS plc by 9.5% during the first quarter, acquiring an additional 6,196 shares to bring its total holdings to 71,748 shares valued at approximately $15.9 million. This occurred despite recent insider selling by STERIS executives totaling about $1.55 million. Analysts maintain a "Moderate Buy" rating with an average price target of $278 for STERIS, which recently traded near $217.94 after reporting slightly missed quarterly EPS but 6.7% revenue growth.
5,000 Shares in STERIS plc $STE Purchased by Louisiana State Employees Retirement System
The Louisiana State Employees Retirement System recently acquired 5,000 shares of STERIS plc (NYSE:STE) valued at approximately $1.106 million during the first quarter. This purchase contributes to STERIS's high institutional ownership, which stands at 94.69%, with other major funds like Vanguard and State Street also increasing their stakes. STERIS reported Q4 earnings slightly below estimates at $2.83 per share, though revenue met expectations at $1.59 billion, and analysts generally rate the stock a "Moderate Buy" with an average target price of $278.
The AMSCO 880 Surgical Table - Steris plc keeps a long-running OR workhorse current
The article highlights the AMSCO 880 Surgical Table by Steris plc as a durable and reliable workhorse in US operating rooms, emphasizing its longevity, high patient capacity, and electrohydraulic system. It discusses how this legacy product contributes to Steris's recurring revenue model through service contracts and parts, making it a significant component of the company's broader strategy despite being an older design. The piece also details its design, functionality, and market positioning within the US healthcare system.
Teleflex Q1 2026 slides: earnings beat amid margin pressure, buyback starts early
Teleflex (NYSE: TFX) exceeded Q1 2026 earnings and revenue expectations despite significant margin pressure from tariffs and integration costs. The company reported adjusted EPS of $1.39 and revenue of $548.3 million, driven by strong performance in the Surgical segment and the recent Vascular Intervention acquisition. Teleflex also announced new leadership, governance enhancements, and an accelerated $1 billion share repurchase authorization starting in Q2 2026, while maintaining its full-year 2026 guidance.
Steris plc. Focus stays on a steady medtech profile.
Steris plc maintains its position as a global medical equipment and infection-prevention company, with its business model anchored in recurring procedural demand across hospitals, life sciences, and surgery centers. The company provides essential sterilization, contamination control, and surgical support services, making its revenue base stable and tied to clinical workflows. Its shares trade on the NYSE, offering investors exposure to a durable medtech franchise.
Does STERIS (STE) Insider Option Exercise Quietly Reframe the Cash Flow and Spending Debate?
STERIS plc director Mohsen Sohi recently exercised options to acquire 3,781 Ordinary Shares, increasing his direct holding to 26,142 shares. This move draws attention as STERIS is known for its steady cash flow and recurring healthcare service demand. The article discusses STERIS's investment narrative, including its share repurchase program and consistent dividends, against the backdrop of ongoing debates about cash flow strength, spending requirements, and potential margin pressures from tariffs and reimbursement changes.
STERIS plc $STE Shares Sold by Boston Trust Walden Corp
Boston Trust Walden Corp reduced its stake in STERIS plc by 3.3% in the first quarter, although it still holds a significant position worth $68.1 million. Despite insider selling by the CEO and a director, institutional investors own 94.69% of the company's stock. STERIS reported quarterly EPS slightly below expectations but saw a 6.7% revenue increase and maintains a "Moderate Buy" consensus rating from analysts with a target price of $278.00.
STERIS (STE) director Mohsen Sohi exercises 3,781 options, surrenders 1,837 shares
STERIS plc director Mohsen Sohi exercised options for 3,781 Ordinary Shares at $71.40 each and surrendered 1,837 shares for $212.30 each in a cashless settlement to cover the option price. Following these transactions, Sohi's direct holdings increased to 26,142 Ordinary Shares. The options were initially received during STERIS's redomiciliation to Ireland in 2019.
Steris plc outlines its healthcare sterilization role as a global provider
Steris plc operates as a global provider of infection prevention and sterilization solutions for healthcare and life science customers. The company offers a combination of equipment, consumables, and services tailored to hospitals, ambulatory surgery centers, laboratories, and pharmaceutical industries. Its business model addresses critical needs in maintaining sterile environments, supporting medical procedures, and ensuring compliance, positioning it to benefit from growing demands in patient safety and healthcare infrastructure worldwide.
Steris PLC stock outperforms competitors on strong trading day
Steris PLC stock (STE) advanced 2.78% to $218.20 on Thursday, outperforming the broader market. This marks the stock's second consecutive day of gains, even as the S&P 500 Index remained mostly unchanged and the Dow Jones Industrial Average rose by 1.14%.
Steris plc steadies operations as healthcare demand supports long-term growth
Steris plc, a global provider of infection prevention and procedural products, is balancing steady demand for its solutions with ongoing operational investments and long-term growth initiatives in global healthcare markets. The company's strategy focuses on expanding its portfolio, investing in new technologies, and broadening its geographic reach to benefit from an aging population and increasing awareness of infection risks. Steris's business model combines one-time equipment sales with recurring revenue from consumables, parts, and services, ensuring a stable revenue stream.
Harbor Investment Advisory LLC Boosts Position in STERIS plc $STE
Harbor Investment Advisory LLC significantly increased its stake in STERIS plc, buying an additional 5,176 shares to own a total of 5,288 shares worth $1.17 million. Analysts maintain a "Moderate Buy" rating for STERIS with
Cento FLEX Scope from Steris plc - flexible endoscope reprocessing for busy US hospitals
The Cento FLEX Scope by Steris plc is an automated, low-temperature endoscope reprocessing system designed for high-volume endoscopy units in US hospitals. It aims to standardize the cleaning and disinfection of flexible endoscopes, which cannot withstand high heat, by integrating processes like pre-cleaning, leak testing, flushing, disinfection, and rinsing. This system helps hospitals comply with infection control guidelines, reduces reliance on manual methods, and provides detailed documentation for traceability, thereby addressing the critical need for effective reprocessing of complex medical devices.
Steris PLC stock underperforms Tuesday when compared to competitors
Steris PLC (STE) stock declined by 1.25% on Tuesday, closing at $210.57, despite a generally positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the second consecutive day of losses for Steris PLC.
Steris plc earnings miss shapes expectations ahead of August update
Steris plc reported modest revenue growth but slightly missed consensus earnings estimates for its fiscal fourth quarter 2026. This small earnings-per-share miss, despite solid top-line growth, has put a focus on the company's next update in early August, which investors anticipate will clarify the longer-term growth narrative and margin expectations. Analysts project Steris's earnings to grow by about 7.7 percent next year, with an estimated next earnings release around August 5, 2026.
Ford Transit Sales Grew Faster Than All Rivals During Q1 2026
Ford Transit sales grew faster than all its rivals in the U.S. during Q1 2026, leading the full-size van segment with a 10 percent increase and 34,048 deliveries. The Transit and E-Series combined gave Ford a dominant 60 percent market share. The article also details significant tech updates for the 2026 Ford Transit model, including SYNC 4 and a 5G modem.
Price to book forward of STERIS plc – HAM:2TG
This article focuses on the "Price to book forward" metric for STERIS plc (HAM:2TG). It appears to be a stub or data-centric page from TradingView, providing no detailed financial analysis but instead presenting a single data point for this financial ratio. The content indicates that the market for HAM:2TG was closed at the time of access.
Pictet Asset Management Holding SA Boosts Position in STERIS plc $STE
Pictet Asset Management Holding SA increased its stake in STERIS plc (NYSE:STE) by 9.2% in the first quarter, bringing its total holdings to 823,649 shares valued at approximately $182.1 million. Several other institutional investors also adjusted their positions, with institutions now owning 94.69% of STERIS. The company reported Q1 earnings of $2.83 per share, slightly below expectations, but revenue increased by 6.7% year-over-year.
Steris PLC stock outperforms competitors despite losses on the day
Shares of Steris PLC (STE) fell 1.13% to $213.24 on Monday, despite a generally positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both rising. This marks the end of a four-day winning streak for the stock.
STE Q1 2019 Earnings Call
The article provides a brief overview of STERIS plc's (STE) stock information, including its current price and after-hours trading. It indicates the availability of various financial data, news, and investor resources related to the company. The content also includes a disclaimer stating that the information provided is for reference only and not investment advice.
Rockefeller Capital Management L.P. Raises Stock Position in STERIS plc $STE
Rockefeller Capital Management L.P. significantly increased its stake in STERIS plc by 59.5% in the fourth quarter, bringing its total holdings to 13,613 shares valued at approximately $3.45 million. This comes as other institutional investors have also adjusted their positions in the medical equipment provider, while company insiders have sold shares. Despite mixed quarterly earnings, analysts maintain a "Moderate Buy" rating with a consensus price target of $278.00 for STERIS.
Assenagon Asset Management S.A. Increases Stake in STERIS plc $STE
Assenagon Asset Management S.A. significantly increased its stake in STERIS plc by 160.6% in the first quarter, bringing its total holdings to 48,846 shares valued at approximately $10.8 million. Other institutional investors like Norges Bank, AQR Capital Management LLC, Boston Partners, Orbis Allan Gray Ltd, and State Street Corp also made substantial changes to their positions. STERIS shares were up 2.4% at $215.59, despite the company reporting mixed earnings with EPS missing estimates but revenue matching expectations.
Price to book forward of STERIS plc (Ireland) – NYSE:STE
This article provides access to the "Price to book forward" financial metric for STERIS plc (Ireland) under its NYSE ticker STE, as available on TradingView. It indicates that the market was closed at the time of access and provides information on data sources and various TradingView features.
STERIS plc Actuals & Estimates (NYSE:STE)
This article provides an overview of STERIS plc (NYSE: STE) stock, including its current price, market capitalization, and analyst forecasts. It details recent financial performance, such as earnings per share and revenue, and outlines future earnings expectations and dividend information. The report also covers historical price data, stock volatility, employee count, and EBITDA.
Steris PLC stock outperforms competitors on strong trading day
Steris PLC (STE) saw its stock rise by 2.41% to $215.67 on Friday, bucking a negative trend in the broader market where both the S&P 500 Index and Dow Jones Industrial Average experienced slight declines. This marked the fourth consecutive day of gains for Steris PLC, leading to its outperformance against competitors in a challenging trading session.
Price to book forward of STERIS plc – BX:STE
This article provides the "Price to book forward" for STERIS plc (STE) on the BX Swiss exchange. It notes that the market is closed with no trades. The core content is limited to this financial metric and general market information.
Sotera Health shares, sector peers and risk management in focus
Sotera Health (SHC) shares, listed on NASDAQ, specialize in health services for medical device and pharmaceutical manufacturers, focusing on sterilization and lab testing. The company's business model, which includes Sterigenics, Nordion, and Nelson Labs, provides risk-management services that are recurring and create long-term customer relationships. Regulatory scrutiny on sterilization methods, particularly EO, impacts the industry, influencing Sotera Health's operational costs and emphasizing expertise in a consolidated market.
Steris plc outlines capital allocation priorities, shares trade steadily on NYSE
Steris plc has updated investors on its capital allocation framework, emphasizing reinvestment in its business, strategic acquisitions, and consistent dividends, while maintaining moderate net leverage. The healthcare sterilization specialist, with a market capitalization of around $20.6 billion, relies on recurring service and consumables revenue to generate robust free cash flow. Analyst consensus remains positive, highlighting the company's stable earnings growth and its defensive position within the medical technology sector.
STERIS plc Actuals & Estimates (FWB:2TG)
This article provides financial actuals and estimates for STERIS plc (FWB:2TG), including income statement, balance sheet, and cash flow data, alongside analyst forecasts. It details the company's stock ticker, price forecasts, historical highs and lows, upcoming earnings reports, and recent financial performance metrics like EPS, revenue, net income, dividends, and EBITDA. The information is sourced from TradingView, offering insights into STERIS plc's financial health and market position.
STE Forecast — Price Target — Prediction for 2027
This article provides a forecast for STERIS plc (STE) stock, including analyst price targets, ratings, and financial data. It covers expected earnings and revenue, dividend information, EBITDA, and employee count. The report aggregates opinions from financial analysts and offers insights into the company's financial performance.
STERIS plc Actuals & Estimates (HAM:2TG)
This article provides an overview of STERIS plc's financial data and analyst estimates, trading under the ticker 2TG on the Hamburg Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, alongside frequently asked questions about stock tickers, forecasts, historical prices, earnings reports, revenue, net income, dividends, employee count, and EBITDA. The stock's next earnings report is set for August 10, 2026, with recent earnings per share at 2.45 EUR, slightly below the estimated 2.47 EUR.
STERIS plc Actuals & Estimates (LS:A2PGLV)
This article provides an overview of STERIS plc's (A2PGLV) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It covers the current stock price, analyst forecasts, historical highs and lows, market capitalization, and dividend information. The report also details recent earnings per share and revenue figures, along with the company's next earnings date and EBITDA.
Price to earnings forward of STERIS plc (Ireland) – NYSE:STE
This article provides the "Price to earnings forward" value for STERIS plc (Ireland) under its NYSE ticker symbol STE. The content is presented as a financial data point from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet.
Enterprise value to revenue forward of STERIS plc (Ireland) – NYSE:STE
This article provides financial information for STERIS plc (Ireland) with the NYSE ticker STE, specifically focusing on its enterprise value to revenue forward metric. The content highlights the company's financial data on the TradingView platform and indicates "No trades" for the market.
Price to sales forward of STERIS plc (Ireland) – NYSE:STE
This article provides the "Price to sales forward" value for STERIS plc (Ireland) under the NYSE:STE ticker. It is a financial data point displayed within a TradingView interface, without additional context or analysis.
Enterprise value to EBIT forward of STERIS plc (Ireland) – NYSE:STE
This article provides financial information for STERIS plc (Ireland) under the NYSE ticker STE, specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or a data point from a larger financial platform, indicating the value and change over a period.
Enterprise value to EBITDA forward of STERIS plc (Ireland) – NYSE:STE
This page from TradingView provides financial information for STERIS plc (Ireland) with the ticker NYSE:STE. Specifically, it focuses on the enterprise value to EBITDA forward metric. The content highlights the company's financials, news, and other market data available through TradingView.
Steris plc consensus stays positive, shares supported by buy ratings
Steris plc maintains a positive analyst consensus on the NYSE, with most covering houses recommending a "Buy" rating. Analysts project a double-digit percentage upside from current levels, citing strong demand for healthcare and recurring revenue streams. The company reported 9% revenue growth for fiscal 2026, driven by its infection-prevention solutions.
2TG Forecast — Price Target — Prediction for 2027
This article provides a forecast for STERIS plc (2TG) stock, including a 1-year price target of 229.17 EUR based on analyst opinions. It details the maximum and minimum price estimates, past price performance, upcoming earnings reports, and financial metrics such as revenue, net income, EBITDA, and dividend information. The company's employee count and methods for buying its stock are also discussed.
SG Americas Securities LLC Sells 51,428 Shares of STERIS plc $STE
SG Americas Securities LLC reduced its stake in STERIS plc by 32.7% in the first quarter, selling 51,428 shares. Insider selling also occurred, with Director Richard C. Breeden and CEO Daniel A. Carestio decreasing their holdings. STERIS reported mixed quarterly results, missing EPS estimates slightly but matching revenue expectations, and raised its quarterly dividend.
STERIS PLC Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
The article provides information about STERIS PLC Unsponsored Brazilian Depositary Receipt (S1TE34) listed on the B3 stock exchange. It indicates that the market is closed with no trades, focusing on financial data and the number of shareholders. The content appears to be a data page from TradingView, offering details for investors researching this specific stock.
Steris PLC stock underperforms Wednesday when compared to competitors despite daily gains
Steris PLC (STE) stock gained 1.95% on Wednesday, closing at $207.17, marking its second consecutive day of increases. Despite this gain, the stock underperformed compared to its competitors, even as the Dow Jones Industrial Average rose and the S&P 500 Index experienced a slight decline.
WST Stock Price and Chart — NYSE:WST
This page provides an overview of West Pharmaceutical Services, Inc. (WST) stock, including its current price, performance metrics, key financial stats, and company information. It also includes various trading ideas and technical analyses from the TradingView community, along with analyst ratings and ETF holdings.
Precision Trading with Steris Plc (ireland) (STE) Risk Zones
Quantitative Research Desk has provided an analysis for Steris Plc (Ireland) (NYSE: STE), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. The analysis identifies a mid-channel oscillation pattern and an exceptional 37.0:1 risk-reward setup, targeting a 10.7% gain against a 0.3% risk. Three distinct trading strategies — Position, Momentum Breakout, and Risk Hedging — are offered to suit different risk profiles.
Steris PLC stock outperforms competitors on strong trading day
Shares of Steris PLC (STE) increased by 1.40% to $203.21 on Tuesday, despite a challenging trading session where the S&P 500 Index and Dow Jones Industrial Average both experienced declines. The company's stock closed 24.58% below its 52-week high of $269.44, set on January 16th.
Steris PLC (STU:2TG) Stock Price & 30 Year Financial Data
This article provides comprehensive 30-year financial data for Steris PLC (STU:2TG), including growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, dividends, and book value. It details the company's market capitalization, enterprise value, and various financial ratios like PE and PB. The data is presented to assist investors in analyzing the historical financial performance of Steris PLC.
